Phase II study of pre and post operative combination chemotherapy using carboplatin and dose dense paclitaxel (dose dense TC therapy) for locally advanced cervical cancer

Phase II study of pre and post operative combination chemotherapy using carboplatin and dose dense paclitaxel (dose dense TC therapy) for locally advanced cervical cancer - SGSG016 study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015184

Enrollment

Registered

2014-09-18

Start date

2014-09-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

FIGO stage Ib2, IIa2, or IIb cervical cancer

Interventions

Carboplatin AUC6 (Day1), Paclitaxel 80mg/m2 (Day1, 8, 15) Q21 Days 3 cycles (Neoadjuvant) Type III hysterectomy Carboplatin AUC6 (Day1), Paclitaxel 80mg/m2 (Day1, 8, 15) Q21 Days 3 cycles (Adjuvant)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Pathologically confirmed cervical cancer. 2. FIGO stage Ib2, IIa2, or IIb. 3. ECOG performance status: 0 to 2 4. Patient with adequate organ function.

Exclusion criteria

Exclusion criteria: 1. Prior chemotherapy nor radiation therapy for cervical cancer. 2. Simultaneous active cancer. 3. Serious coexisting illness 4. Carrier of viral hepatitis 5. Active infection 6. Interstitial pneumonia

Design outcomes

Primary

Measure	Time frame
2 year recurrence free survival	—

Secondary

Measure	Time frame
objective response rate, pathological response rate, 2 year overall survival, toxicity, site of recurrence, completion rate of protocol therapy	—

Countries

Japan

Contacts

Public ContactSHOJI NAGAO

Hyogo Cancer Center Gynecologic Oncology

nagao@hp.pref.hyogo.jp078-929-1151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026